6.7.4. non-metastatic crpc. frequent psa testing men treated adt resulted earlier detection biochemical progression. men approximately one-third develop bone metastases within two years, detected conventional imaging . men crpc detectable clinical metastases using bone scan ct-scan, baseline psa level, psa velocity psa-dt associated time first bone metastasis, bone mfs os . factors may used deciding patients evaluated metastatic disease. consensus statement pca radiographic assessments detection advanced recurrence (radar) group suggested bone scan ct scan psa reached 2 ng/ml negative, repeated psa reached 5 ng/ml, every doubling psa based psa testing every three months asymptomatic men . symptomatic patients undergo relevant investigations regardless psa level. sensitive imaging techniques like psma pet/ct whole-body mri, patients diagnosed early mcrpc . remains unclear use psma pet/ct setting improves outcome. three large phase iii rcts, prosper , spartan aramis , evaluated mfs primary endpoint patients nmcrpc (m0 crpc) treated enzalutamide (prosper) vs. placebo apalutamide (spartan) vs. placebo darolutamide (aramis) vs. placebo ,respectively (see table 6.7.1). m0 status established ct bone scans. patients high risk development metastasis short psa-dt ≤ ten months included. patient characteristics trials revealed two-thirds participants psa-dt < six months. trials showed significant mfs benefit. three trials showed survival benefit follow-up 30 months. view long-term treatment ar targeting agents asymptomatic patients, potential aes need taken consideration patient informed accordingly. table 6.7.1: randomised phase iii controlled trials – nmcrpc studyinterventioncomparisonselection criteriamain outcomesaramis2019, 2020adt + darolutamideadt + placebonmcrpc;baselinepsa > 2 ng/mlpsa-dt < 10 mo.59% reduction distant progression deathmedian mfs: darolutamide 40.4 vs placebo 18.4 mo;31% reduction risk deathhr = 0.69 (95% ci: 0.53–0.88)p = 0.003prosper2018, 2020adt + enzalutamideadt + placebonmcrpc;baselinepsa > 2 ng/mlpsa-dt < 10 mo.71% reduction distant progression deathmedian mfs: enzalutamide 36.6 vs placebo 14.7 months;27% reduction risk deathhr = 0.73 (95% ci: 0.61–0.89)p = 0.001spartan2018, 2021adt + apalutamideadt + placebonmcrpc;baselinepsa > 2 ng/mlpsa-dt < 10 mo.72% reduction distant progression deathmedian mfs: apalutamide 40.5 vs placebo 16.2 months;22% reduction risk deathhr = 0.78 (95% ci: 0.64–0.96)p = 0.0161 adt = androgen-deprivation therapy; ci = confidence interval; hr = hazard ratio; mfs = metastasis-freesurvival; nmcrpc = non-metastatic castrate-resistent prostate cancer; psa-dt = prostate-specific antigen doubling time.